Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA17VD)

• Drug Name: Semorinemab Drug Info
• Synonyms: RO7105705

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMA17VD

Molecule-Related Drug Atlas

Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Semaglutide	DMAGFOD	Type-2 diabetes	5A11	Approved	[3]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[4]
Exenatide	DMYHBKN	Inflammation	1A00-CA43.1	Approved	[5]
Dulaglutide	DMYXBV3	Type-2 diabetes	5A11	Approved	[6]
Lixisenatide	DM0QJDC	Type-2 diabetes	5A11	Approved	[7]
Pramlintide	DM0EZ9Q	Type-1/2 diabetes	5A10-5A11	Approved	[4]
Albiglutide	DM1JEGF	Type-2 diabetes	5A11	Approved	[7]
Tirzepatide	DMQNMAT	Type 2 diabetes	5A11	Approved	[8]
Efpeglenatide	DMKA2PI	Type-2 diabetes	5A11	Phase 3	[9]
GLP-1	DMR6YH3	Diabetic complication	5A2Y	Phase 3	[3]

Drug(s) Targeting Microtubule-associated protein tau (MAPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[10]
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[11]
TRx0237	DM0QNF4	Alzheimer disease	8A20	Phase 3	[12]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[13]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[14]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[15]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[11]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[15]
Bepranemab	DMRQIJO	Alzheimer disease	8A20	Phase 2	[16]
JNJ-63733657	DMMKWGJ	Alzheimer disease	8A20	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]
Microtubule-associated protein tau (MAPT)	TTS87KH	TAU_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03828747) A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [2] Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
• [4] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [5] Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
• [8] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of TauRx.
• [11] Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
• [12] Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
• [13] Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
• [14] PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
• [17] ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.